"Everyone who wants out has probably already done their selling," says Nate Pile, who sees a "sidways to up' market. In his Nate's Notes, the advisor sees opportunity in a trio of techs.

"My experience with market cycles continues to suggest to me that the odds favor a 'sideways or up' market over the next several months.

"Meanwhile, Apple (NASDAQ: AAPL) is technically still stuck in a trading range, I am very pleased with the leadership it has shown in the market over the past several weeks.

Continue reading Tech trio: AAPL, ERTS & NVDA

Tech trio: AAPL, ERTS & NVDA originally appeared on BloggingStocks on Thu, 12 Mar 2009 11:20:00 EST. Please see our terms for use of feeds.

"While I've watched video game maker Electronic Arts (NASDAQ: ERTS) for many years, I've never felt it was cheap," says growth stock specialist Nate Pile.

In his Nate's Notes, he now says, "I am thrilled to see the stock price finally experience the sort of pullback that justifies a buy rating; indeed, I wasn't interested at $50 four months ago, but at $17 today, I can't help but get excited."

"Over the years, Electronic Arts has amassed an impressive library of titles. In particular, you may be familiar with the entire Sims collection, as well as the company's extensive lineup of sports games (including Madden NFL and Tiger Woods PGA Tour, for example).

"In addition, Spore is a recently introduced hit, and some other titles you may be familiar with (or at least seen in TV commercials) include Need For Speed, Medal of Honor, and Rock Band.

Continue reading Electronic Arts (EA): A value in video gaming?

Electronic Arts (EA): A value in video gaming? originally appeared on BloggingStocks on Wed, 28 Jan 2009 13:15:00 EST. Please see our terms for use of feeds.

Two leading advisors with noted expertise in the biotech sector have both been long-term fans of Celgene (NASDAQ: CELG), both holding the stock in their respective model portfolios.

Here, Nate Pile, editor of Nate's Notes, and John McCamant, editor of The Medical Technology Stock Letter, each take a look at the encouraging prospects for this biotechnology firm.

Nate Pile explains, "Now that the Pharmion merger is behind us, it appears that investors are once again
recognizing Celgene for what it is - namely, one of the premier stories in the biopharmaceutical space.

"As I have said a number of times before, if I could only own one biotech stock for the next ten years, Celgene would be it... and I encourage you to make it a 'first choice' for your portfolio as well!

"The stock is likely to exhibit its usual volatility around the company's upcoming earnings report, but I encourage you to take advantage of any sell-off that may occur to aggressively add to your position in this market leader. CELG is now considered a strong buy under $60 and a buy under $68."

John McCamant states, "Celgene had some good news of late on the thalidomide front. The company has received approval of the application to expand the drug's label to treat newly diagnosed multiple myeloma (MM) patients in Australia.

Continue reading Biotech experts bet on Celgene (CELG)

Biotech experts bet on Celgene (CELG) originally appeared on BloggingStocks on Mon, 05 May 2008 11:35:00 EST. Please see our terms for use of feeds.